Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

 
 
 
 
 
 
 
 
 
 

MOFOXIN

Quick Overview

Our aim is to reach out to the globe within shortest possible time frame


To promote this objective, not only we distribute and market our Anti-infective range of products globally through our distribution channels but we also undertake ‘contract manufacturing’& ‘formulation development ’of our wide range of generic products such as  Mofoxin which contain  Moxifloxacin Hydrochloride equivalent to Moxifloxacin 400 mg.

Mofoxin

Double click on above image to view full picture

Zoom Out
Zoom In

Details

Composition:

Each film coated tablet contains:

Moxifloxacin Hydrochloride equivalent to Moxifloxacin 400 mg

Description:

moxifloxacin is a fourth generation synthetic fluoroquinolone. It has in vitro activity against a wide range of gram-positive, gram-negative, atypical and anaerobic pathogens. The bactericidal action of MOFOXIN  results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair. Pharmacodynamic investigations have demonstrated that MOFOXIN  exhibits a concentration dependent killing rate.

Indications:

       MoxfloxacinTablets are indicated for the treatment of adults (>/= 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below.

  • Acute Bacterial Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis .
  • Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae,methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis.
  • Community Acquired Pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains*), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydia pneumoniae .
  • Uncomplicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes .
  • Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species .
  • Complicated Skin and Skin Structure Infections caused by methicillin-susceptibleStaphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae .

 Dosage and administration:

The dose of MOFOXIN  is 400 mg (orally or as an intravenous infusion) once every 24 hours. The duration of therapy depends on the type of infection as described below.

Infection

Daily Dose

Duration

Acute Bacterial Sinusitis

400 mg

10 days

 

Acute Bacterial Exacerbation of Chronic Bronchitis

400 mg

5 days

 

Community Acquired

Pneumonia        

400 mg

7-14 days

Uncomplicated Skin and Skin Structure Infections

400 mg

7 days

Complicated Skin and Skin Structure Infections

400 mg

7-21 days

Complicated Intra-Abdominal Infections

400 mg

5-14 days

 

Contraindications:

MOFOXIN  is contraindicated in persons with a history of hypersensitivity to moxifloxacin or any member of the quinolone class of antimicrobial agents.

Presentation: 

Blister of 5 tablets. 

 
OUR PRESENCE:
FIND US ON: